Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.
Ruebsam, F., Webber, S.E., Tran, M.T., Tran, C.V., Murphy, D.E., Zhao, J., Dragovich, P.S., Kim, S.H., Li, L.S., Zhou, Y., Han, Q., Kissinger, C.R., Showalter, R.E., Lardy, M., Shah, A.M., Tsan, M., Patel, R., Lebrun, L.A., Kamran, R., Sergeeva, M.V., Bartkowski, D.M., Nolan, T.G., Norris, D.A., Kirkovsky, L.(2008) Bioorg Med Chem Lett 18: 3616-3621
- PubMed: 18487044
- DOI: https://doi.org/10.1016/j.bmcl.2008.04.066
- Primary Citation of Related Structures:
3CO9 - PubMed Abstract:
Pyrrolo[1,2-b]pyridazin-2-one analogs were discovered as a novel class of inhibitors of genotype 1 HCV NS5B polymerase. Structure-based design led to the discovery of compound 3 k, which displayed potent inhibitory activities in biochemical and replicon assays (IC(50) (1b)<10nM; EC(50) (1b)=12 nM) as well as good stability towards human liver microsomes (HLM t(1/2)>60 min).
Organizational Affiliation:
Anadys Pharmaceuticals, Inc., 3115 Merryfield Row, San Diego, CA 92121, USA. fruebsam@anadyspharma.com